News
This was the stock's second consecutive day of losses.
Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...
In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the ...
Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.
Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...
Lynozyfic’s global sales are projected to reach $707 million by 2031.
The stock's fall snapped a two-day winning streak.
The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback